Pediatric Cardiac Surgery Department, University Hospital Erlangen, Erlangen, Germany.
Ann Thorac Surg. 2011 Mar;91(3):816-22. doi: 10.1016/j.athoracsur.2010.10.040.
Improved survival after Norwood stage 1 palliation is giving more patients the opportunity to reach stage 2 palliation; thus, more patients are exposed to the risk of interstage death.
A single-center review of patients who underwent stage 1 palliation from January 1998 to December 2007 (n = 58) was performed. Pulmonary blood flow was established either by a modified Blalock-Taussig-shunt (mBTS, n = 33) or a right ventricle-to-pulmonary artery conduit (RVPAC, n = 25).
Hospital, interstage, and 1-year survival was not significantly different between groups. However, Kaplan-Meier survival analysis reflected a significantly higher survival probability for RVPAC patients until the age of 120 days (RVAPC, 92% ± 5% [standard error of the mean]; 95% confidence interval, 82 to 100; mBTS, 63% ± 9%; 95% confidence interval, 48 to 82; p = 0.01). During a 1-year follow-up, all 11 nonsurvivors with mBTS died at an age younger than 120 days, including 2 patients with early stage 2 palliation. In contrast, besides 2 early deaths, all RVPAC patients (n = 5) showed later attrition at an age older than 120 days while awaiting stage 2 palliation. Interstage death occurred significantly later among RVPAC patients (RVPAC, 146 ± 60 days versus mBTS, 81 ± 23 days; p = 0.01). After stage 2 palliation, all patients with RVPAC survived, including 7 patients with surgery at an age younger than 120 days. All interstage and late deaths were related to compromising cardiac lesions with no statistical difference between groups.
After Norwood stage 1 palliation, survival was improved with RVPAC for the first 4 months. However, a loss of the favorable primary outcome was present by delaying stage 2 palliation beyond the age of 120 days. Progressive volume load as a result of conduit regurgitation may play a crucial role for later attrition. Residual lesions should be addressed early to preserve cardiac function.
Norwood 一期姑息术后存活率的提高,使更多患者有机会接受二期姑息术,因此,更多患者面临着术间死亡的风险。
对 1998 年 1 月至 2007 年 12 月期间行一期姑息术的患者(n=58)进行单中心回顾性研究。肺动脉血流的建立方式为改良 Blalock-Taussig 分流术(mBTS,n=33)或右心室至肺动脉导管(RVPAC,n=25)。
两组患者的住院、术间和 1 年生存率无显著差异。然而,Kaplan-Meier 生存分析显示,RVPAC 组患者在 120 天龄时的生存率明显更高(RVPAC,92%±5%[均数标准差];95%置信区间,82%至 100%;mBTS,63%±9%;95%置信区间,48%至 82%;p=0.01)。在 1 年随访期间,所有行 mBTS 术且未存活的 11 例患者均于 120 天龄前死亡,其中包括 2 例早期行二期姑息术的患者。相反,除了 2 例早期死亡外,所有 RVPAC 组患者(n=5)在等待二期姑息术期间均于 120 天龄后出现较晚的死亡。RVPAC 组患者的术间死亡时间明显晚于 mBTS 组(RVPAC,146±60 天;mBTS,81±23 天;p=0.01)。二期姑息术后,所有接受 RVPAC 治疗的患者均存活,包括 7 例于 120 天龄前手术的患者。所有术间和晚期死亡均与心脏病变有关,两组间无统计学差异。
在 Norwood 一期姑息术后,RVPAC 在前 4 个月可提高生存率。然而,由于在 120 天龄后延迟行二期姑息术,导致主要结局不理想。由于导管反流导致的逐渐增加的容量负荷可能对晚期死亡起关键作用。应早期解决残余病变,以维持心脏功能。